A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs TAK 935 (Primary)
- Indications Dravet syndrome; Encephalopathy; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 02 Nov 2018 Status changed from active, no longer recruiting to completed.
- 18 Jul 2018 According to an Ovid Therapeutics media release, topline data are expected in the fourth quarter of calendar year 2018.
- 18 Jul 2018 According to an Ovid Therapeutics media release,Status changed from recruiting to active, no longer recruiting.